376 related articles for article (PubMed ID: 31416990)
1. Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus.
Tan K; Chow WS; Leung J; Ho A; Ozaki R; Kam G; Li J; Choi CH; Tsang MW; Chan N; Lee KK; Chan KW
Hong Kong Med J; 2019 Aug; 25(4):312-319. PubMed ID: 31416990
[No Abstract] [Full Text] [Related]
2. New Medications for the Treatment of Diabetes.
Garg SK; Giordano D
Diabetes Technol Ther; 2019 Feb; 21(S1):S160-S171. PubMed ID: 30785325
[No Abstract] [Full Text] [Related]
3. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials.
Yamada T; Shojima N; Noma H; Yamauchi T; Kadowaki T
Diabetes Obes Metab; 2018 Jul; 20(7):1755-1761. PubMed ID: 29451721
[TBL] [Abstract][Full Text] [Related]
4. Are sodium-glucose cotransporter-2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation.
Ahangar Davoodi M; Daneshmand MA; Rezaei T
J Diabetes; 2024 Jul; 16(7):e13570. PubMed ID: 38923174
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
Li K; Xu G
J Diabetes; 2019 Aug; 11(8):645-655. PubMed ID: 30565398
[TBL] [Abstract][Full Text] [Related]
6. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes.
Akturk HK; Rewers A; Garg SK
Curr Opin Endocrinol Diabetes Obes; 2018 Aug; 25(4):246-250. PubMed ID: 29794497
[TBL] [Abstract][Full Text] [Related]
7. NICE guidance on dapagliflozin with insulin for type 1 diabetes.
Adler AI; Ting S; Dent R; Latimer N
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):750-751. PubMed ID: 31488391
[No Abstract] [Full Text] [Related]
8. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
Sims H; Smith KH; Bramlage P; Minguet J
Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
[TBL] [Abstract][Full Text] [Related]
9. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus.
Fattah H; Vallon V
Drugs; 2018 May; 78(7):717-726. PubMed ID: 29663292
[TBL] [Abstract][Full Text] [Related]
10. Using Insulin to Treat Poorly Controlled Type 2 Diabetes in 2020.
Hirsch IB; Gaudiani LM
JAMA; 2020 Jun; 323(23):2419-2420. PubMed ID: 32442246
[No Abstract] [Full Text] [Related]
11. Severe hypoglycaemia the "tip of the iceberg": an underestimated risk in both type 1 and type 2 diabetic patients.
Halimi S
Diabetes Metab; 2015 Apr; 41(2):105-6. PubMed ID: 25824635
[No Abstract] [Full Text] [Related]
12. Perioperative Considerations for the Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes.
Peacock SC; Lovshin JA; Cherney DZI
Anesth Analg; 2018 Feb; 126(2):699-704. PubMed ID: 28786838
[No Abstract] [Full Text] [Related]
13. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes.
Abdelgadir E; Rashid F; Bashier A; Al Saeed M; Khalifa A; Alawadi F; Hassanein M
Diabetes Metab Syndr; 2019; 13(5):2927-2932. PubMed ID: 31425958
[TBL] [Abstract][Full Text] [Related]
14. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Cefalo CMA; Cinti F; Moffa S; Impronta F; Sorice GP; Mezza T; Pontecorvi A; Giaccari A
Cardiovasc Diabetol; 2019 Feb; 18(1):20. PubMed ID: 30819210
[TBL] [Abstract][Full Text] [Related]
15. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
Kalyani RR
N Engl J Med; 2021 Apr; 384(13):1248-1260. PubMed ID: 33789013
[No Abstract] [Full Text] [Related]
16. Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
Shamchuk A; Doulla M; Jetha M
CMAJ; 2021 Sep; 193(35):E1385-E1388. PubMed ID: 34493565
[No Abstract] [Full Text] [Related]
17. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients.
Hasan SS; Kow CS; Bain A; Kavanagh S; Merchant HA; Hadi MA
Expert Opin Pharmacother; 2021 Feb; 22(2):229-240. PubMed ID: 33054481
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemia: New Definitions and Regulatory Implications.
Ratner RE
Diabetes Technol Ther; 2018 Jun; 20(S2):S250-S253. PubMed ID: 29873525
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycaemia: costs, insulins and prevention.
Holt RI
Diabet Med; 2016 Apr; 33(4):419-20. PubMed ID: 26995756
[No Abstract] [Full Text] [Related]
20. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
